Oluwole, Olalekan O.

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 6,030

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial

Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 2,286

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

Locke, F. L., Miklos, D. B., Jacobson, C. A., Perales, M.-A., Kersten, M.-J., Oluwole, O. O., Ghobadi, A., Rapoport, A. P., McGuirk, J., Pagel, J. M., et al. (2022) · New England Journal of Medicine

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 1,607

Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium

Nastoupil, L. J., Jain, M. D., Feng, L., Spiegel, J. Y., Ghobadi, A., Lin, Y., Dahiya, S., Lunning, M., Lekakis, L., Reagan, P., et al. (2020) · Journal of Clinical Oncology

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 801

Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2019) · Journal of the National Comprehensive Cancer Network

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 570

Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

Locke, F. L., Rossi, J. M., Neelapu, S. S., Jacobson, C. A., Miklos, D. B., Ghobadi, A., Oluwole, O. O., Reagan, P. M., Lekakis, L. J., Lin, Y., et al. (2020) · Blood Advances

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 489

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results

Mailankody, S., Matous, J. V., Chhabra, S., Liedtke, M., Sidana, S., Oluwole, O. O., Malik, S., Nath, R., Anwer, F., Cruz, J. C., et al. (2023) · Nature Medicine

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 257

Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies

Baik, A. H., Oluwole, O. O., Johnson, D. B., Shah, N., Salem, J.-E., Tsai, K. K., & Moslehi, J. J. (2021) · Circulation Research

Chemotherapy-induced cardiotoxicity and mitigationCancer Immunotherapy and Biomarkers

Cited by 138